AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer
A phase 2 trial of ivonescimab, gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by First Affiliated Hospital Xi'an Jiaotong University, not yet recruiting.
Overview
AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer is a phase 2 interventional study registered as NCT07767994 by First Affiliated Hospital Xi'an Jiaotong University, with a registry enrolment figure of 22 participants, started 2026-08-28 and due to reach its primary completion in 2028-06-30. Interventions recorded: AK112, Gemcitabine, Cisplatin, Albumin-Bound Paclitaxel /nab-Paclitaxel. Conditions listed: Gallbladder Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialDurvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialGemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialCTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
- TrialGemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Gemcitabine and the tag gallbladder-deep-dive.
- TrialMulticenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
- TrialGemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
- TrialAn Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
- TrialStudy of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.